Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor HistologyPRNewsWire • 11/22/22
Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of CancerPRNewsWire • 11/17/22
Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference - (Transcript)Seeking Alpha • 11/16/22
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo NodularisPRNewsWire • 11/11/22
Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC)PRNewsWire • 11/08/22
Aflibercept 8 mg Late-breaking Data Presented at Retina Society in Diabetic Macular Edema and Wet Age-related Macular DegenerationPRNewsWire • 11/04/22
Regeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and DisordersPRNewsWire • 11/03/22
Regeneron Pharmaceuticals Tops Quarterly Expectations Despite Covid ShortfallInvestors Business Daily • 11/03/22
Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) Wins Prestigious 2022 Prix Galien USA Best Biotechnology Product AwardPRNewsWire • 10/28/22
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA® (aflibercept) InjectionPRNewsWire • 10/21/22
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?Investors Business Daily • 10/20/22
Regeneron (REGN) Drug Gets Positive CHMP View for Cervical CancerZacks Investment Research • 10/17/22
Immune-Onc Therapeutics Initiates Expansion Cohorts for IO-108 and Enters into Clinical Supply Agreement with RegeneronBusiness Wire • 10/17/22